Bram Goorden discusses IXICO growth plans - ICYMI

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO, Bram Goorden, talked with Proactive about the company's interim results, highlighting strong revenue growth, expanding demand in Alzheimer's disease clinical trials and the company's evolving TechBio strategy. Goorden said IXICO delivered “23% growth of revenues” alongside “38% growth of order book versus the same half last year,” adding that the company now has visibility over “95%” of expected revenues for financial year 2026.